A Single Dose-escalation Study of Cytisine in Adult Smokers

Phase 1

Completed

• Conditions: Smoking Cessation
• Interventions: Drug: placebo; Drug: cytisine

• Registration Number: NCT03848208
• Lead Sponsor: Achieve Life Sciences

Brief Summary

The objectives of this study are:

1. To assess the tolerability and safety of cytisine as a single oral dose.

2. To define the Cmax levels associated to the occurrence of dose-limiting adverse events.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2019-02-19
• Study First Submitted QC: 2019-02-19
• Study First Posted: 2019-02-20
• Study Start: 2019-02-28
• Primary Completion: 2019-09-12
• Study Completion: 2019-09-12
• Status Verified: 2020-08
• Results First Submitted: 2020-08-26
• Results First Submitted QC: 2020-08-26
• Last Update Submitted: 2020-08-26
• Results First Posted: 2020-09-17
• Last Update Posted: 2020-09-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 74

Inclusion Criteria

Subjects must meet ALL of the following criteria to be eligible for inclusion into the study:

1. Free written informed consent prior to any procedure required by the study.
2. Male or female subjects, age ≥18 years, at the time of signing the informed consent.
3. Current daily cigarette smokers (averaging at least 10 cigarettes per day in the past 30 days).
4. Expired air carbon monoxide (CO) ≥10 ppm.
5. Able to swallow multiple tablets at one time.
6. Able to fully understand, comply with all study requirements.

Read More

Exclusion Criteria

Subjects meeting ANY of the following exclusion criteria will NOT be eligible for inclusion into the study at screening.

1. Known hypersensitivity to cytisine or any of the excipients.

2. Known severe hypersensitivity to any other drug.

3. Positive urinary drugs of abuse screen, determined within 28 days before cytisine/placebo dosing.

4. Positive ethanol breath test.

5. Clinically significant abnormal serum chemistry, hematology, coagulation or urinalysis values within 28 days of randomization (i.e. requiring treatment or monitoring).

6. Clinically significant abnormalities in 12-lead echocardiogram (ECG) determined after minimum of 5 minutes in supine position within 28 days of randomization (i.e. requiring treatment or further assessment).

7. Body Mass Index (BMI) classification for being underweight (<18.5 kg/m2) or having ≥Class 2 obesity (≥35 kg/m2).

8. History of acute myocardial infarction, unstable angina, stroke, cerebrovascular incident, cardiac arrhythmia, or hospitalization for congestive heart failure.

9. Blood pressure ≥160/100 mmHg, measured on the dominant arm, after at least 3 minutes in supine position.

10. Creatinine clearance (CrCl) <80 mL/min (estimated with the Cockroft-Gault equation).

11. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.0 x the upper limit of normal (ULN).

12. Any inability to comply with study restrictions (See Section 9)

13. Any inability or difficulty in fasting.

14. Difficulty in donating blood on either arm.

15. If woman of childbearing potential, positive result in serum beta-human chorionic gonadotropin (hCG) pregnancy test.

16. Women who are breast-feeding.

17. Subjects who do not agree to use acceptable methods of birth control during the study (See Section 9.4).

18. Participation in a clinical study with an investigational drug within the previous 2 months.

19. Participation in more than 2 clinical trials within the previous 12 months.

20. Any other reason that the investigator views the subject should not participate or would be unable to fulfill the requirements for the study.

    Subjects meeting ANY of the following exclusion criteria will NOT be eligible for inclusion into the study at admission to each cohort.

21. Any recent disease or condition or treatment that, according to the Investigator, would put the subject at undue risk due to study participation.

22. Positive urinary drugs of abuse screen.

23. Positive ethanol breath test.

24. If female of childbearing potential, positive result in urine beta-hCG pregnancy test.

25. Any other reason that the investigator views the subject should not participate or would be unable to fulfill the requirements for the study.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Cohort 1: Placebo	placebo	Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
Cohort 3: Placebo	placebo	Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
Cohort 4: Placebo	placebo	Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
Cohort 8: Placebo	placebo	Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
Cohort 2: Placebo	placebo	Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
Cohort 6: Placebo	placebo	Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
Cohort 5: Placebo	placebo	Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
Cohort 7: Cytisine 24.0 mg	cytisine	Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
Cohort 7: Placebo	placebo	Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
Cohort 9: Placebo	placebo	Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
Cohort 1: Cytisine 6.0 mg	cytisine	Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
Cohort 2: Cytisine 9.0 mg	cytisine	Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
Cohort 3: Cytisine 12.0 mg	cytisine	Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
Cohort 4: Cytisine 15.0 mg	cytisine	Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
Cohort 5: Cytisine 18.0 mg	cytisine	Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
Cohort 6: Cytisine 21.0 mg	cytisine	Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
Cohort 9: Cytisine 30.0 mg	cytisine	Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
Cohort 8: Cytisine 27.0 mg	cytisine	Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.

Primary Outcome Measures

Name	Time	Method
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Study Discontinuation	From first dose of study drug through Day 6	An adverse event (AE) is defined as any untoward medical occurrence that does not necessarily have to have a causal relationship with the treatment. A serious AE is any untoward medical occurrence or effect, that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; results in a congenital abnormality or birth defect; or is an important medical event which requires medical intervention to prevent one of the above. Treatment emergent events are those that occurred after the first dose of study drug.
Pharmacokinetics: Time to Occurrence of Cmax (Tmax)	Day 1: Pre-dose (within 30 minutes prior to dosing), 15, 30, 40, 50 minutes and 1, 1.25, 1.5, 1.75, 2, 2.5, and 3 hours (+/-2 minutes) post-dose
Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax)	Day 1: Pre-dose (within 30 minutes prior to dosing), 15, 30, 40, 50 minutes and 1, 1.25, 1.5, 1.75, 2, 2.5, and 3 hours (+/-2 minutes) post-dose

Trial Locations

Locations (1)

BlueClinical; 🇵🇹 Porto, Portugal